A collaborative, storewide effort
Drug Store News speaks with John Fegan, VP pharmacy at Winn-Dixie.
Drug Store News: What is the vision behind Winn-Dixie’s health-and-wellness initiatives?
John Fegan: Our stated mission is to earn trust and loyalty every day. Trust comes from having the best products and the best services available at the right price. From the pharmacy perspective, we [also] would want to provide the most inclusive information available in the marketplace to assure the overall health and well-being of the patients that we serve. [Our patients] don’t have to worry about shopping around to find a health-and-wellness item. They know we’re going to have it. That’s [part of] establishing the trust, [and] that is key…. If you do that, then shoppers are going to return, [and] they’re going to be loyal to you.
DrSN: What goals are you trying to achieve through Winn-Dixie’s health-and-wellness initiatives?
Fegan: The endgame is that we want the entire store to be part of the initiative. It isn’t just pharmacy; it isn’t just [health and beauty care]. It truly is a collaborative effort among the entire team here at Winn-Dixie. It isn’t pharmacy trying to wag the dog; it’s the entire dog moving in the same direction, [and] that’s providing the information, the healthy products and the selection to the consumers who are using our stores. Every department will be pulling in the same direction to provide the health-and-wellness program that we set out to provide.
DrSN: What have you learned?
Fegan: Two things. First, the associates love it. The associates are involved in something that’s unique, something that’s different, something they can get behind, something they can learn from.
The second is that our customers are getting an education. It’s a different time, and when you used to go to the old drug store, you didn’t have the services, the selections, [all of this health] information that’s available to you. When we’re doing health testing and immunizations, [or making] follow-up calls on medicines, and the people are walking down our aisles and seeing information about a healthy product we may be selling, that creates a ‘wow’ factor among our customers. It’s an education process for them as shoppers, and they’re absorbing it.… So, the benefit behind educating the consumer is the short answer, [coupled with] an acceptance and involvement by the associates.
Walgreens offering free review sessions to Medicare Part D beneficiaries
DEERFIELD, Ill. Walgreens now is offering free review sessions to Medicare Part D beneficiaries at all of its more than 7,100 pharmacies throughout the country.
Following the open enrollment period for Medicare Part D insurance plans, Walgreens is assisting those beneficiaries who’ve made changes to their prescription drug coverage. Review sessions with Walgreens pharmacists are available daily by appointment through Jan. 31, and are designed to help patients maximize their plan benefits.
Review sessions include:
- A review of beneficiary’s current medications, tiers within their selected plan, co-pays and cost-savings opportunities
- Discussion of available health and wellness services including pneumonia and shingles vaccinations and 90-day prescription benefits
- Checks for potential drug interactions
Watson files FDA application for generic LoSeasonique
MORRISTOWN, N.J. Watson Labs, a subsidiary of specialty pharmaceutical company Watson Pharmaceuticals, has filed an abbreviated new drug application to the Food and Drug Administration for an oral contraceptive.
Watson is seeking approval to market its levonorgestrel and ethinyl estradiol (0.10-mg/0.02-mg) oral contraceptive product prior to the expiration of U.S. Patent No. 7,615,545, which is owned by Duramed Pharmaceuticals, a subsidiary of Teva. Watson’s levonorgestrel and ethinyl estradiol product is a generic version of Teva’s LoSeasonique, which is indicated for the prevention of pregnancy.
On Nov. 23, 2009, pursuant to the Hatch-Waxman Act, Watson notified Duramed that its ANDA requesting approval from the FDA for a generic version of LoSeasonique contained a paragraph IV certification asserting that the LoSeasonique patent is invalid, unenforceable and/or not infringed. Teva Women’s Health filed suit against Watson on Jan. 6, 2010 in the U.S. District Court for the District of New Jersey seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. 7,615,545. Based on available information, Watson believes it may be entitled to 180 days of generic market exclusivity or shared exclusivity should its product receive approval.